These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857 [TBL] [Abstract][Full Text] [Related]
6. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma. Yamane T; Takaoka A; Kita M; Imai Y; Senda M Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262 [TBL] [Abstract][Full Text] [Related]
7. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150 [TBL] [Abstract][Full Text] [Related]
8. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer. Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733 [TBL] [Abstract][Full Text] [Related]
9. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose. Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552 [TBL] [Abstract][Full Text] [Related]
10. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832 [TBL] [Abstract][Full Text] [Related]
11. FDG uptake heterogeneity evaluated by fractal analysis improves the differential diagnosis of pulmonary nodules. Miwa K; Inubushi M; Wagatsuma K; Nagao M; Murata T; Koyama M; Koizumi M; Sasaki M Eur J Radiol; 2014 Apr; 83(4):715-9. PubMed ID: 24418285 [TBL] [Abstract][Full Text] [Related]
12. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487 [TBL] [Abstract][Full Text] [Related]
14. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging. Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224 [TBL] [Abstract][Full Text] [Related]
16. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. Herrmann K; Ott K; Buck AK; Lordick F; Wilhelm D; Souvatzoglou M; Becker K; Schuster T; Wester HJ; Siewert JR; Schwaiger M; Krause BJ J Nucl Med; 2007 Dec; 48(12):1945-50. PubMed ID: 18006614 [TBL] [Abstract][Full Text] [Related]
17. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts]. Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377 [TBL] [Abstract][Full Text] [Related]
18. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes. Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845 [TBL] [Abstract][Full Text] [Related]
19. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. Cobben DC; van der Laan BF; Maas B; Vaalburg W; Suurmeijer AJ; Hoekstra HJ; Jager PL; Elsinga PH J Nucl Med; 2004 Feb; 45(2):226-31. PubMed ID: 14960640 [TBL] [Abstract][Full Text] [Related]
20. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]